ProCE Banner Activity

Phase I/II Study: Belantamab Mafodotin With Lenalidomide + Dexamethasone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma

Slideset Download
Conference Coverage
Belantamab mafodotin appears to be safe, with a manageable ocular safety profile, when given with lenalidomide and dexamethasone in transplant-ineligible NDMM.

Released: December 16, 2021

Expiration: December 15, 2022

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Daiichi Sankyo, Inc.

GlaxoSmithKline

Incyte Corporation

Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation